Relation Therapeutics Secures $55 Million Novartis Partnership for AI-Driven Atopic Disease Target Discovery
核心洞察
Relation Therapeutics (搜索) has entered a strategic collaboration with Novartis worth $55 million upfront, with potential milestone payments reaching $1.7 billion for discovering novel targets in atopic diseases.
The partnership leverages Relation's AI-powered 'lab-in-a-loop' platform that uses human genetics and single-cell multi-omics to identify and validate therapeutic targets before clinical testing.
The collaboration focuses on atopic diseases including allergic rhinitis (搜索), asthma (搜索), and atopic dermatitis (搜索), which affect hundreds of millions of people worldwide and are driven by immune dysregulation.
UK-based AI and multi-omics company Relation Therapeutics (搜索) has secured a strategic multi-programme collaboration with Novartis worth $55 million upfront to discover and advance novel targets for atopic diseases. The partnership includes potential milestone payments of up to $1.7 billion tied to preclinical, development, regulatory, and commercial achievements, along with tiered royalties on product sales.
The collaboration pairs Relation's AI-powered drug discovery platform with Novartis's expertise in immuno-dermatology to identify and validate first-in-class targets in atopic diseases driven by immune dysregulation. Atopic diseases, including allergic rhinitis (搜索), asthma (搜索), and atopic dermatitis (搜索), affect hundreds of millions of people worldwide and are characterized by exaggerated immunoglobulin E (搜索) (IgE) immune responses.
AI-Driven Target Discovery Platform
Relation's competitive advantage lies in its 'lab-in-a-loop' process, which uses algorithms to identify targets through human genetics, single-cell multi-omics directly from human tissue, and functional assays. The results are continuously fed back into the system to refine the discovery process, designed to minimize clinical failure risk by ensuring robust target validation before human testing begins.
"Our technology defines the molecular pathways in diseased tissue compared to healthy tissue to help discover possible new therapeutics for medicines," said David Roblin, Relation's chief executive. "Together with Novartis' development and commercialisation capabilities, we can potentially deliver medicines that transform the standard of care."
Under the collaboration terms, Relation will lead observational studies to generate functional 'cell atlases' based on patient tissue samples that capture disease states. This approach represents a significant shift from traditional drug discovery methods by incorporating human data generation capabilities from the earliest stages of target identification.
Strategic Partnership Momentum
This partnership represents Relation's second major collaboration with a big pharma company, following two deals with GSK announced almost exactly one year earlier. The GSK collaborations, focused on fibrotic diseases (搜索) and osteoarthritis (搜索) targets, included $45 million upfront, $63 million in additional funding, and $200 million in milestones per target across both programs.
Benjamin Swerner, COO and founder of Relation, noted that this marks "Relation's third major collaboration in 12 months," highlighting the company's rapid expansion in the pharmaceutical partnership space.
Novartis's Immuno-Dermatology Focus
Novartis has positioned immuno-dermatology as a key pillar of its R&D strategy, with an active pipeline including BTK (搜索) inhibitor remibrutinib for food allergies (搜索) and Dren Bio (搜索)-partnered bispecific antibody GHZ339 (搜索) for atopic dermatitis (搜索), both currently in phase 2 trials.
The collaboration with Relation aligns with this strategic focus, potentially expanding Novartis's target portfolio in allergic diseases through AI-driven discovery approaches that promise more precise target validation.
Additional Funding Round
Concurrent with the Novartis announcement, Relation revealed it had raised an additional $26 million from existing investors including NVentures (搜索) (NVIDIA (搜索)'s venture capital arm), DCVC (搜索), and Magnetic Ventures (搜索). According to Roblin, this funding will "strengthen the base" of the company's mission to "discover the next generation of medicines through technology."
The combination of strategic partnerships and continued investor support positions Relation at the forefront of AI-driven drug discovery, with total committed funding and potential milestones now exceeding $2 billion across its pharmaceutical collaborations.